Skip to main content
Log in

Generalization of distribution – Free confidence intervals for bioavailability ratios

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The confidence interval approach to bioavailability assessment depends first on selection of the confidence level, usually 95%, and then determination of the confidence limits for the expected bioavailability ratio AUC(Test)/AUC(Reference). In practice, however, it is sometimes of greater interest to know the probability that the expected bioavailability will fall below a critical value, for example 0.75, or within a clinically set bioequivalence range, for example 0.80 to 1.25. Up to now, posterior probability distributions have been suggested, based on classical analysis of variance (ANOVA) with its rather restrictive assumptions, including that of a (logarithmic) normal distribution. In this report, a distribution-free confidence interval based on the Wilcox-on signed-rank statistic has been generalized so that confidence probabilities can be obtained for any given confidence limits. In the case of unimodal and almost symmetrical sampling distributions, the results obtained are very similar to those of the ANOVA-based posterior probability distribution. However, skewed or multimodal sampling distributions are better reflected by the proposed distribution-free method, and more valid information is obtained in these cases, as demonstrated by examples.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Fluehler H, Hirtz J, Moser HA (1981) An aid to decision-making in bioequivalence assessment. J Pharmacokinet Biopharm 9: 235–243

    Article  PubMed  CAS  Google Scholar 

  2. Fluehler H, Grieve AP, Mandallaz D, Mau J, Moser HA (1983) Bayesian approach to bioequivalence assessment; an example. J Pharm Sci 72: 1178–1181

    Article  PubMed  CAS  Google Scholar 

  3. Hollander M, Wolfe DA (1973) Nonparametric statistical methods. Wiley, New York, pp 35–38

    Google Scholar 

  4. Kramer WG, Kolibash AJ, Bathala MS, Visconti JA, Lewis RP, Reuning RH (1977) Digoxin bioavailability: Evaluation of a generic tablet and proposed FDA guidelines. J Pharm Sci 66: 1720–1722

    Article  PubMed  CAS  Google Scholar 

  5. Mandallaz D, Mau J (1981) Comparison of different methods for decision-making in bioequivalence assessment. Biometrics 37: 213–222

    Article  PubMed  CAS  Google Scholar 

  6. Steinijans VW, Diletti E (1983) Statistical analysis of bioavailability studies: Parametric and nonparametric confidence intervals. Eur J Clin Pharmacol 24: 127–136

    Article  PubMed  CAS  Google Scholar 

  7. Wijnand HP, Timmer CJ (1983) Mini-computer programs for bioequivalence testing of pharmaceutical drug formulations in two-way cross-over studies including a survey of current parametric evaluation techniques. Computer Programs Biomed 17: 73–88

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steinijans, V.W., Diletti, E. Generalization of distribution – Free confidence intervals for bioavailability ratios. Eur J Clin Pharmacol 28, 85–88 (1985). https://doi.org/10.1007/BF00635713

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00635713

Key words

Navigation